Tuberculosis is spreading with renewed vigour globally as are its more virulent strains like multi-drug-resistant TB and extensively drug-resistant TB. Even as the bacteria mutates and there is urgent need to deal with the many inadequacies of the present treatment regimen, new drugs backed by innovative research are conspicuously absent. A new candidate anti-TB drug proposed to be tried by the Open Source Drug Discovery initiative with the Council of Scientifi c and Industrial Research offers a ray of hope.
